The top six anti‐HCC core targets (c‐Myc, ESR1, EGFR, HSP90AA1, CCND1, and ERBB2) were validated for differential expression in LIHC samples, showing a strong correlation with HCC progression (Figure S7B). Here, HSP90AA1 is linked to hepatocellular carcinoma.